Ochiai Ryuji, Saitou Katsuyoshi, Suzukamo Chika, Osaki Noriko, Asada Takashi
Biological Science Laboratories, Kao Corporation, Sumida-ku, Tokyo, Japan.
Health Care Food Research Laboratories, Kao Corporation, Sumida-ku, Tokyo, Japan.
J Alzheimers Dis. 2019;72(4):1209-1216. doi: 10.3233/JAD-190757.
Mild cognitive impairment (MCI) is a global-scale issue, due in large part to the rapidly growing elderly population. The main polyphenol contained in coffee beans, chlorogenic acid (CGA), improves attention in healthy individuals. The utility of CGAs for treating MCI, however, has not been evaluated.
To determine the effects of continuous CGA intake on cognitive function, especially attention, in patients diagnosed with MCI.
The study was a randomized controlled crossover trial including 34 patients with MCI. Participants were randomly divided into two groups: Those who first ingested a placebo beverage and those who first ingested an active beverage containing CGAs (553.6 mg/bottle) twice daily for 12 weeks. After a 4-week washout period, the subjects ingested the other beverage (i.e., placebo or active beverage) in the same manner. Endpoint measures included scores on the Japanese version of the Mini-Mental State Examination (MMSE), the Japanese version of the Alzheimer's Disease Assessment Scale-cognitive component (ADAS-cog) testing overall cognitive function, and the Japanese version of the Trail Making Test (TMT-A, TMT-B) testing attention, along with the results of blood tests to evaluate safety.
In the TMT-B test, participants had a significantly reduced number of errors while ingesting the CGA beverage as compared with the placebo beverage (p < 0.05), although there was no difference in test completion time. Scores in the MMSE, ADAS-cog, and TMT-A did not differ significantly between conditions.
Continuous intake of CGAs appears to improve attention and executive function among cognitive functions in MCI.
轻度认知障碍（MCI）是一个全球性问题，很大程度上归因于老年人口的快速增长。咖啡豆中含有的主要多酚成分绿原酸（CGA）可改善健康个体的注意力。然而，绿原酸对治疗MCI的效用尚未得到评估。
确定连续摄入CGA对诊断为MCI的患者认知功能，尤其是注意力的影响。
该研究为随机对照交叉试验，纳入34例MCI患者。参与者被随机分为两组：一组先饮用安慰剂饮料，另一组先饮用含CGA（553.6毫克/瓶）的活性饮料，每天两次，持续12周。在4周的洗脱期后，受试者以相同方式饮用另一种饮料（即安慰剂或活性饮料）。终点指标包括日本版简易精神状态检查表（MMSE）评分、日本版阿尔茨海默病评估量表认知部分（ADAS-cog）测试整体认知功能、日本版连线测验（TMT-A、TMT-B）测试注意力，以及评估安全性的血液检测结果。
在TMT-B测试中，与饮用安慰剂饮料相比，参与者饮用CGA饮料时的错误数量显著减少（p<0.05），尽管测试完成时间没有差异。MMSE、ADAS-cog和TMT-A的评分在不同条件之间没有显著差异。
持续摄入CGA似乎可改善MCI患者认知功能中的注意力和执行功能。
